Clinical trials: AD - Alzheimer's Disease
Alzheimer's Disease, Mild Cognitive Impairment
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
To Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]flutemetamol Positron Emission Tomography (PET) Images.
- Trial name
- NCT01672827
- Testing
- [18F]Flutemetamol
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Wisconsin Alzheimer's Disease Research Center, Wisconsin Registry for Alzheimer's Prevention
Speech Pattern Evaluation and Analysis for Knowledge of AD
The goal of this observational study is to validate changes in speech as a measure of cognition in individuals at increased risk of Alzheimer's disease and related dementias (ADRD).
- Trial name
- SPEAK-AD (NCT06230783)
- Testing
- TalkTracker
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimer Disease, Psychosis
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
- Trial name
- NCT06947941
- Testing
- KarXT, KarX-EC
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Early Onset Alzheimer Disease
48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease
Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.
- Trial name
- NCT04002583
- Testing
- Computer assisted ambulatory electroencephalogram
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Dementia
Optimal Medication Management in Alzheimer's Disease and Dementia
The study objective is to conduct a pragmatic deprescribing intervention for people with Alzheimer's Disease or Related Dementia with Multiple Chronic Conditions (ADRD-MCC) so that these patients are on 'just right' medication…
- Trial name
- Optimize (NCT03984396)
- Testing
- Educational Materials - Patient & Clinician
- Where
- United States
- Volunteers
- 7,398 people
- Sponsor
- Kaiser Permanente
Alzheimer Disease, Dementia
Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease
This study seeks to evaluate the utility and efficacy of the Non-Contact Sleep Quality Monitor System when used to monitor the sleep quality of individuals living in long-term care (LTC) with either Alzheimer's Disease (AD) or…
- Conditions
- Alzheimer Disease, Dementia, Sleep Disturbance
- Trial name
- NCT06045988
- Testing
- Non-Contact Sleep Quality Monitor System
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer's Disease (Incl Subtypes), Dementia
Improvisational Movement for People With Memory Loss and Their Caregivers
Dementia is a progressive decline in cognition that impairs a person's ability to perform activities of daily living. Changes in mood, gait, and balance are prominent secondary symptoms of Alzheimer's dementia that can…
- Conditions
- Alzheimer's Disease (Incl Subtypes), Dementia, Mild Cognitive Impairment
- Trial name
- IMOVE (NCT03333837)
- Testing
- Dance Group, Non-Group Dance, Social Group
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Wake Forest University Health Sciences
Neurodegenerative Disease, Dementia
Cognition and Affective Research in China
This is a prospective cohort study of patients with cognitive impairment mood disorders and behavioral disorders. Comprehensive baseline and longitudinal follow-up assessments include clinical and epidemiological data, cognitive…
- Conditions
- Neurodegenerative Disease, Dementia, Alzheimer's Disease, Parkinson's Disease
- Trial name
- CARE (NCT07833267)
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer Disease (AD)
Alzheimer's Disease Treated With Vagus Nerve Stimulation
The goal of this clinical trial is to evaluate the safety and efficacy of vagus nerve stimulation (VNS) for treating Alzheimer's disease (AD) in patients aged 50-80 years with mild cognitive impairment to moderate Alzheimer's…
- Trial name
- Advant (NCT06923007)
- Testing
- Vagus Nerve Stimulation
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Alzheimer's Disease
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition…
- Trial name
- AD (NCT02947893)
- Testing
- Nilotinib Capsule(s) Once a Day by Mouth
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Georgetown University
Alzheimer's Disease (Incl Subtypes), Dementia
Sirtuin-NAD Activator in Alzheimer's Disease
The primary objectives are to: 1. To determine whether MIB-626, after its daily oral administration, penetrates the blood-brain barrier in humans by measuring the cerebrospinal fluid (CSF) concentrations of MIB-626 and its key…
- Trial name
- NCT05040321
- Testing
- MIB-626
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Brigham and Women's Hospital
Frontotemporal Dementia, Alzheimer Disease
Young Onset Dementia - the Difficult Diagnosis and the Stressful Life for the Whole Family
People diagnosed with young onset dementia are today mostly assigned to the same healthcare services as people developing dementia at an older age.
- Trial name
- NCT02055092
- Where
- Norway
- Volunteers
- 250 people
- Sponsor
- Norwegian Centre for Ageing and Health
Alzheimer's Disease
European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to…
- Trial name
- NCT00217763
- Testing
- 3APS
- Where
- 69 sites in Belgium, France and 8 more
- Volunteers
- 930 people
- Sponsor
- Bellus Health Inc. - a GSK company
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease
Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a…
- Trial name
- NCT07659964
- Testing
- Metronome
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Participants Must be Women Aged 25 Years or Older, Participants Should Have no Self-reported History of Heart Disease or Stroke
RCT of HeartBot in Women
The goal of this clinical trial is to find out whether an app-based program called HeartBot II, which uses an artificial intelligence (AI) chatbot, can help improve women's awareness and knowledge of heart attacks in women.
- Conditions
- Participants Must be Women Aged 25 Years or Older, Participants Should Have no Self-reported History of Heart Disease or Stroke, Participants Should Have no Terminal Illness or Diagnosed Cognitive Impairment, Including Alzheimer's Disease, Participants Should Not be a Healthcare Professionals or Healthcare Trainees
- Trial name
- HeartBot II (NCT07416734)
- Testing
- HeartBot II Program, Waitlist Control
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
Dementia, Dementia Alzheimer Type
Plans4Care: Personalized Dementia Care on Demand
The Plans4Care study is a research study funded by the National Institute on Aging (Grant# R44AG084365). The Plans4Care app is designed to help family caregivers address over 90 common care challenges such as behavioral symptoms…
- Conditions
- Dementia, Dementia Alzheimer Type, Alzheimer Dementia (AD), Memory Loss
- Trial name
- NCT07115251
- Testing
- Plans4Care
- Volunteers
- 160 people
- Sponsor
- Plans4Care Inc
Depression
Prevention of Depression in Spouses of People With Cognitive Impairment
This study evaluates the effectiveness of a problem-solving training program in preventing depression in the spouses or family caregivers of persons with mild cognitive impairment or early dementia.
- Trial name
- NCT00321971
- Testing
- PST-MCI/AD Caregiving, NT-MCI/AD Caregiving
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Mild Cognitive Impairment, Alzheimer's Disease
Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations
This is an open-label study to evaluate Aftobetin-HCl and florescence detection as measured by the Sapphire II device. Performance of Part I of the study has been completed (15 subjects received a single administration of…
- Trial name
- NCT02928211
- Testing
- Sapphire II, Aftobetin-HCl, Positron Emission Tomography
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Cognoptix, Inc.
Transcranial Direct Current Stimulation, Dementia
The Dose Finding Study of DAOIB Added to tDCS for AD
This is a 26-week randomized, double-blind, placebo-controlled trial. We will enroll patients with aMCI or mild AD. All patients will receive 2 weeks of tDCS (5 sessions per week, 10 sessions in total) during the first 2 weeks of…
- Trial name
- NCT05006781
- Testing
- DAOIB
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Chang Gung Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.